EFR3A and pancreatic adenocarcinoma: We find that pancreatic adenocarcinoma patients with an EFR3A genomic alteration (almost exclusively gene amplification, Fig. 1b) have a 26% reduction in overall median survival compared to patients without an EFR3A genomic alteration (i.e. 15.3 versus 20.8 months, Fig. 1c).